Spotlighting Comprehensive Preclinical Development of Antifolate ADCs to Enter IND Phase for a Novel Drug-Linker Mechanism - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Spotlighting Comprehensive Preclinical Development of Antifolate ADCs to Enter IND Phase for a Novel Drug-Linker Mechanism

11:00 am - Wednesday 14th October 2026

Presenting development of a novel antifolate linker-payload platform, leveraging a toxin class with a clinically validated mechanism of action
Exploring in vitro and in vivo preclinical development and physicochemical properties of frontrunner antifolate ADC program
Laying out pharmacology studies and dose range finding investigation in the lead up to antifolate ADC IND studies

Speakers:

Wim Dokter

Wim Dokter

Chief Scientific Officer

Byondis B.V.